138 related articles for article (PubMed ID: 21520453)
1. An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
Brutti P; Gubbiotti S; Sambucini V
Stat Med; 2011 Jun; 30(14):1648-64. PubMed ID: 21520453
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian predictive two-stage design for phase II clinical trials.
Sambucini V
Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
[TBL] [Abstract][Full Text] [Related]
3. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
Thall PF; Russell KE
Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
[TBL] [Abstract][Full Text] [Related]
4. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
Mayo MS; Gajewski BJ
Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
[TBL] [Abstract][Full Text] [Related]
5. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
Zohar S; Chevret S
J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
[TBL] [Abstract][Full Text] [Related]
6. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
Sambucini V
Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
[TBL] [Abstract][Full Text] [Related]
8. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
9. A Bayesian design and analysis for dose-response using informative prior information.
Smith MK; Marshall S
J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
[TBL] [Abstract][Full Text] [Related]
10. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
11. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
Zohar S; Teramukai S; Zhou Y
Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
[TBL] [Abstract][Full Text] [Related]
12. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of a Simon 2-Stage phase II clinical trial design incorporating toxicity monitoring.
Ray HE; Rai SN
Contemp Clin Trials; 2011 May; 32(3):428-36. PubMed ID: 21256247
[TBL] [Abstract][Full Text] [Related]
14. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Thall PF; Cook JD; Estey EH
J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
16. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
17. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
Zhang Y; Mietlowski W; Chen B; Wang Y
J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
[TBL] [Abstract][Full Text] [Related]
18. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
19. Operating characteristics of a Simon two-stage phase II clinical trial design incorporating continuous toxicity monitoring.
Ray HE; Rai SN
Pharm Stat; 2012; 11(2):170-6. PubMed ID: 22232063
[TBL] [Abstract][Full Text] [Related]
20. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]